SeaCrest Wealth Management LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 9.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 118,286 shares of the biopharmaceutical company’s stock after selling 11,768 shares during the period. SeaCrest Wealth Management LLC’s holdings in Pfizer were worth $4,354,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Morgan Stanley lifted its stake in Pfizer by 6.4% during the third quarter. Morgan Stanley now owns 46,069,866 shares of the biopharmaceutical company’s stock worth $1,690,763,000 after purchasing an additional 2,777,676 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Pfizer by 0.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 39,996,916 shares of the biopharmaceutical company’s stock worth $1,467,887,000 after buying an additional 143,779 shares in the last quarter. Sanders Capital LLC increased its holdings in shares of Pfizer by 2.2% during the third quarter. Sanders Capital LLC now owns 28,895,978 shares of the biopharmaceutical company’s stock worth $1,183,645,000 after buying an additional 613,967 shares in the last quarter. California Public Employees Retirement System increased its holdings in shares of Pfizer by 3.0% during the fourth quarter. California Public Employees Retirement System now owns 19,516,941 shares of the biopharmaceutical company’s stock worth $718,419,000 after buying an additional 572,666 shares in the last quarter. Finally, Jensen Investment Management Inc. increased its holdings in shares of Pfizer by 7.3% during the third quarter. Jensen Investment Management Inc. now owns 11,168,803 shares of the biopharmaceutical company’s stock worth $409,895,000 after buying an additional 761,980 shares in the last quarter. Hedge funds and other institutional investors own 67.36% of the company’s stock.
Shares of PFE stock traded down $0.34 during trading hours on Tuesday, hitting $33.92. 397,934 shares of the company were exchanged, compared to its average volume of 35,504,273. The firm has a fifty day simple moving average of $35.94 and a 200 day simple moving average of $37.10. The company has a current ratio of 1.40, a quick ratio of 1.13 and a debt-to-equity ratio of 0.76. Pfizer Inc. has a 52-week low of $27.88 and a 52-week high of $43.08. The stock has a market capitalization of $188.54 billion, a price-to-earnings ratio of 22.10, a P/E/G ratio of 2.79 and a beta of 0.70.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.46 by ($0.04). Pfizer had a return on equity of 24.88% and a net margin of 17.85%. The company had revenue of $11.68 billion for the quarter, compared to analysts’ expectations of $11.32 billion. During the same quarter in the previous year, the business earned $0.55 EPS. The company’s revenue for the quarter was up 11.8% on a year-over-year basis. Sell-side analysts anticipate that Pfizer Inc. will post 2.89 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 5th. Stockholders of record on Friday, January 29th will be paid a dividend of $0.39 per share. The ex-dividend date is Thursday, January 28th. This represents a $1.56 annualized dividend and a dividend yield of 4.60%. This is a positive change from Pfizer’s previous quarterly dividend of $0.38. Pfizer’s dividend payout ratio (DPR) is presently 52.88%.
Several research analysts have recently issued reports on PFE shares. DZ Bank reiterated a “buy” rating and set a $41.00 price target on shares of Pfizer in a report on Wednesday, February 3rd. TheStreet upgraded Pfizer from a “c+” rating to a “b-” rating in a report on Wednesday, November 25th. JPMorgan Chase & Co. set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Wednesday, February 3rd. Royal Bank of Canada set a $42.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Monday, January 4th. Finally, Barclays increased their price objective on shares of Pfizer from $35.00 to $37.00 and gave the stock an “equal weight” rating in a research report on Friday, December 4th. Eleven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and an average price target of $39.38.
Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.
Recommended Story: Why is the Consumer Price Index (CPI) important?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.